Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 10.
doi: 10.1002/nau.70106. Online ahead of print.

Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments

Karis Buford  1 , Kenneth M Peters  1   2 , Claus Riedl  3 , Nagendra Nath Mishra  4 , Wyndaele Jean Jacques  5 , Sándor Lovász  6 , Rui Almeida Pinto  7 , Lori Birder  8
Affiliations
Review

Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments

Karis Buford et al. Neurourol Urodyn. .

Abstract

Aims: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition marked by chronic pain and voiding dysfunction, often without a clear cause. Management of which often requires a multidisciplinary approach, as well as multiple therapeutic interventions.

Methods: This review characterizes mechanisms and limitations of currently available treatment modalities for IC/BPS, as well as novel and investigational therapies.

Results: Conservative and supportive therapies include cognitive therapies, dietary and fluid management, pelvic floor exercises and bladder training. Additionally, pelvic floor directed therapies such as physical therapy, injections and nerve blocks should be considered. Cystoscopy with hydrodistension is both a diagnostic and therapeutic intervention. Currently available oral therapies include: pentosan polysulfate, amitriptyline, hydroxyzine, silodosin, and non-opioid medications such as cyclobenzaprine. Immunotherapies include cyclosporine and tacrolimus. Available intravesical therapies include dimethyl sulfoxide, lidocaine, oxybutynin, and glycosaminoglycan substitution treatment. Neuromodulation is also available including sacral and pudendal neuromodulation. Finally, we explore emerging therapies and drug delivery systems.

Conclusions: In this review, we present currently available treatment options for IC/BPS. These include conservative therapies, oral medications, intravesical therapies, and neuromodulation. Novel and investigational therapies are presented as well as promise for future directions.

Keywords: Hunner's lesions; bladder pain syndrome; chronic pain; interstitial cystitis; pelvic pain; therapeutic options; therapies.

PubMed Disclaimer

References

    1. J. M. Teichman and R. Moldwin, “The Role of the Bladder Surface in Interstitial Cystitis/Painful Bladder Syndrome,” Canadian Journal of Urology 14, no. 4 (2007): 3599–3607.
    1. W. R. Yu, J. F. Jhang, Y. H. Jiang, and H. C. Kuo, “The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome,” Biomedicines 12, no. 9 (2024): 2051, https://doi.org/10.3390/biomedicines12092051.
    1. L. C. McKernan, C. G. Walsh, W. S. Reynolds, L. J. Crofford, R. R. Dmochowski, and D. A. Williams, “Psychosocial Co‐Morbidities in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): A Systematic Review,” Neurourology and Urodynamics 37, no. 3 (2018): 926–941, https://doi.org/10.1002/nau.23421.
    1. D. Engeler, A. P. Baranowski, B. Berghmans, et al., “EAU Guidelines on Chronic Pelvic Pain,” European Urology, accessed January 2025, https://uroweb.org/guidelines/chronic-pelvic-pain.
    1. J. Q. Clemens, D. R. Erickson, N. P. Varela, and H. H. Lai, “Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome,” Journal of Urology 208, no. 1 (2022): 34–42, https://doi.org/10.1097/JU.0000000000002756.

LinkOut - more resources